goserelin and Brain-Neoplasms

Gonadotropin-releasing hormone (GnRH) receptor, a rhodopsin-like G-protein coupled receptor (GPCR) family member involved in GnRH signaling, is reported to be expressed in several tumors including glioblastoma multiforme (GBM), one of the most malignant and aggressive forms of primary brain tumors. However, the molecular targets associated with GnRH receptor are not well studied in GBM or in other cancers. The present study aims at investigating the effect of GnRH agonist (Gosarelin acetate) on cell proliferation and associated signaling pathways in GBM cell line, LN229.. The treatment with different concentrations of GnRH agonist showed a reduction in cell proliferation with a maximum reduction of 48.2% observed at 10. The study suggests a possible link of GnRH signaling with EGFR signaling pathways likely via KNG1. KNG1 inhibitors may be investigated independently or in combination with GnRH agonist for therapeutic applications.

Topics: Animals; Antineoplastic Agents, Hormonal; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, Liquid; Computational Biology; Glioblastoma; Gonadotropin-Releasing Hormone; Goserelin; Humans; Proteomics; Receptors, LHRH; Signal Transduction; Tandem Mass Spectrometry

Although there have been major improvements in the management of breast cancer, with a rapidly falling death rate despite an increasing incidence of the disease, metastatic breast cancer remains common and the cause of death in nearly 12 000 women annually in the UK. Numerous treatment options are available that either target the tumour or reduce the complications of the disease. Clinical decision making depends on knowledge of the extent and biology of the disease and available drug options, an understanding of the functional status, and also the wishes and expectations of the individual patient. In addition, the organisation of services and support of the patient are essential components of high-quality care. The National Institute for Health and Clinical Excellence (NICE) has produced guidelines for the treatment of advanced breast cancer, which in some areas have perhaps failed to appreciate the complexity of patient management. This guidance document aims to provide succinct practical advice on the treatment of metastatic breast cancer, highlight some limitations of the NICE guidelines, and provide suggestions for management where available data are limited.

Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Decision Making; Female; Goserelin; Humans; Ovariectomy; Patient Care Team; Postmenopause; Premenopause; Radiotherapy; Tamoxifen; United Kingdom

We report the case of an 80-year-old man who presented with relapsing prostate cancer and cerebral metastases which showed evidence of radiological and clinical response to androgen suppression alone without additional whole brain radiotherapy.

Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Goserelin; Humans; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prostatic Neoplasms; Tomography, X-Ray Computed; Transurethral Resection of Prostate